US 12,239,735 B2
Lipid nanoparticles for delivering mRNA vaccines
Danilo Casimiro, Paris (FR); Sudha Chivukula, Paris (FR); Kirill Kalnin, Paris (FR); Timothy Plitnik, Paris (FR); Timothy Tibbitts, Paris (FR); Frank Derosa, Paris (FR); Anusha Dias, Paris (FR); Rebecca L. Goldman, Paris (FR); Hardip Rajeshbhai Gopani, Paris (FR); Shrirang Karve, Paris (FR); Asad Khanmohammed, Paris (FR); and Priyal Patel, Paris (FR)
Assigned to SANOFI, Paris (FR)
Filed by SANOFI, Paris (FR)
Filed on Nov. 7, 2023, as Appl. No. 18/503,327.
Application 18/503,327 is a continuation of application No. 18/458,767, filed on Aug. 30, 2023.
Application 18/458,767 is a continuation of application No. 17/520,200, filed on Nov. 5, 2021, granted, now 11,771,652, issued on Oct. 3, 2023.
Claims priority of provisional application 63/212,523, filed on Jun. 18, 2021.
Claims priority of provisional application 63/110,965, filed on Nov. 6, 2020.
Claims priority of application No. 21315198 (EP), filed on Oct. 13, 2021.
Prior Publication US 2024/0091154 A1, Mar. 21, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/127 (2006.01); A61K 9/1272 (2025.01); A61K 39/00 (2006.01); A61K 39/145 (2006.01); A61K 39/39 (2006.01); A61P 31/16 (2006.01)
CPC A61K 9/1272 (2013.01) [A61K 39/145 (2013.01); A61K 39/39 (2013.01); A61P 31/16 (2018.01); A61K 2039/53 (2013.01); A61K 2039/55555 (2013.01)] 45 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising a nucleic acid molecule encapsulated in a lipid nanoparticle (LNP), wherein the LNP comprises:
a cationic lipid GL-HEPES-E3-E12-DS-4-E10 at a molar ratio between 35% and 45%,
dimyristoyl-PEG2000 (DMG-PEG2000) at a molar ratio between 0.25% and 2.75%,
cholesterol at a molar ratio between 20% and 35%, and
1,2-dioleoyl-SN-glycero-3-phosphoethanolamine (DOPE) at a molar ratio of between 25% and 35%,
wherein all the molar ratios are relative to the total lipid content of the LNP,
wherein the nucleic acid molecule encodes an antigen derived from Propionibacterium acnes.